Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


Background: Patient-reported outcome (PRO) measures have been increasingly implemented in routine care to aid in clinical decision-making. However, the prognostic value of PRO measures as a tool for decision making is not easily interpreted by clinicians. Our aims were to explore the prognostic value of PRO measures at disease progression and the changes in PRO measures between treatment start (baseline) and disease progression. Patients and Methods: Since 2014, patients with lung cancer have completed an electronic version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and LC-13 before every outpatient visit at the Department of Oncology, Hospital Unit West, Jutland, Denmark. The patients’ responses were used in routine care. Patients receiving palliative antineoplastic treatment were eligible for analysis if the questionnaire had been completed at the initiation of first-line treatment and at disease progression. The prognostic value of the scores was evaluated using a Cox proportional hazard model. A P value < .01 was considered statistically significant. Results: A total of 94 screened patients were included. At disease progression, survival could be predicted from the absolute score of the global health scale, 3 functional scales (physical, role, emotional), and 7 symptom scales (fatigue, pain, dyspnea, hemoptysis, lung cancer dyspnea, chest pain). In addition, changes in hemoptysis, dysphagia, dyspnea, and chest pain predicted for survival at progression. Conclusion: PRO measures used in routine care can provide clinicians with relevant prognostic information about patients with lung cancer at disease progression. These results show the potential value of PRO measures when used in clinical decision-making. The patient-reported outcomes (PROs) used in routine care are not easily interpreted. We evaluated symptom development during first-line palliative treatment using electronic PROs from 94 patients with advanced lung cancer. We identified specific symptom scales that predict for survival at disease progression. These results can aid in the clinical interpretation of PROs used for decision-making.

TidsskriftClinical Lung Cancer
StatusAccepteret/In press - 2020

Bibliografisk note

Funding Information:
This work was supported by the Danish Cancer Society (grants R184-A11805 , 2017), the Max Wørzner and Wife Inger Wørzner's Memorial Fund and the Department of Oncology, Hospital Unit West Juland . We thank all patients and clinical staff for ongoing support to the clinical use of patient-reported outcome measures during treatment in the Department of Oncology, Regional Hospital West Jutland. Thanks to Morten Pilgaard for language revision of our report. A special thanks to the Head of the Department, Senior Consultant Hanne Linnet, for innovative and proactive thinking concerning the implementation of patient-reported outcomes in clinical practice.

Publisher Copyright:
© 2020 The Author(s)

Copyright 2020 Elsevier B.V., All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 207564031